Member Info for doze

They are the equivalent of PD in the UK and AVCT will have submitted the application to a notified body the equivalent of MHRA in the EU. All that is required is for the notified body to uphold the science in the independant report of clinical evaluation along with end user data from Medusa and batch info from ABDX/medusa/GAH. The major hurdle being the science though this is actually the simplest aspect but regulators have a mindset that seems to be inimical to science.

Yes, The power of the Affimer.....to date not catered for by regulators. I have done further thinking and now conclude this independant, 'not peer reviewed yet' report is part of the submission for clinical evaluation to a notified body, probably in Spain. The Paul Ehrlich Institut used for nucleocapsid can be bypassed with this report when accepted by a notified body prepared to break ranks with this different spike protein in vitro report. This would also be a peer review proxy.
This places the report on more urgent level of importance and any criticism of it is a huge back stab of Avacta's hopes for home use retail sales. I also think the queue for evaluating should not be so long as the nucleocapsid route but may be held up while the 'courage' to approve is built up.

I expect PEI get most of the work in the EU evaluating tests. They are pricey https://bimedis.com/roche-cobas-6000-m30252 and no point having oversupply in the compliant EU not to mention the expertise required to operate them but is it all misplaced creating a structure rewarding the few who keep a grip on the process. It would explain AS's lack of progress and the virus spread. Spike proteins indicate infectiousness.

The publication link reposted to save looking for it
https://www.medrxiv.org/content/10.1101/2021.10.28.21265544v1.full.pdf

If clinical evaluation procedures at the Paul Ehrlich Istitut prepare for innoculating an in vitro sample spiking with nucleocapsid target then it is likely they have not been replicating the spike protein characterisation. HUA trials are done by Medusa and pass most likely and they get attached by default to a device appraisal when it is OKed by the institut, much as the CV was CE Marked for professional use (I only assume this is the protocol)
When this evaluation is done at the PEI home use sales can begin
For the scientists among us, I am shooting in the dark without knowing how to check up but I am trying to be logical and I am assuming PD and PEI follow similar procedures. I am also assuming PEI is the notified body for EU devices- MHRA and PD rolled into one.

Perhaps approach from a different direction. 50 alternative LFDs for comparison used and AffiDX came out on top. Preparations are for spike protein whereas all EU ones are nucleocapsid. Notified body like PD need to get with it to detect infectiousness.

Woodsmith will somehow be central t offsetting AAL GHG foorprint
https://www.lse.co.uk/rns/AAL/anglo-american-ambition-to-halve-scope-3-emissions-7s3r68u9ningxwi.html
As a responsible producer of diamonds (through De Beers), copper, platinum group metals, premium quality iron ore and metallurgical coal for steelmaking, and nickel - with crop nutrients in development - we are committed to being carbon neutral across our operations by 2040.

Unfortunately the Government shot their bolt with Innova. To have confidence in another test (AffiDX) it has to have a good track record as level playing field is order of the day. Good sales data for our LFD will be a vote of confidence.

"it will take a LOT for avacta to change the game here and shape the market and this is many many years away"
The World has to change post equity easing. Governments have leveraged the semiconductor revolution and now they need a new opportunity. Biotech, if the regulators can speed up the game can save on a health budget and increase healthiness therefore productivity. 44% of UK gov spend goes on NHS?

Anglo still committed even if it costs more- appraisal was inevitably going to throw up something but progress “ahead of expectations” combined with "construction schedule and future revenues" (affected by pandemic and associated macro issues) resulted in the impairment charge which would have sunk Sirius. I am glad the project goes on.
Worth remembering npk fertilser production is probably much more disadvantaged versus polyhalite due to current energy hikes and cop26 influence favours Woodsmith due to energy saving and increased field yields.

Each cog in the AVCT growth story has its own responsibility and a specific one needs to pursue a specific strategy which respects the whole hence a new update, 2 months after the last to further the establishment of affimers as mainstream biotech.

It is, in my opinion, this type of IP evasion by #AVCT which will get them noticed. This is why they are working on B12 assays quietly. Not because it is a huge money spinner (though 200m at 7.2% CAGR is not to sniffed at for a £300m m cap) but because they know as soon as youWhich will detect ‘active’ B12 and enable #AVCT to work around the existing IP (antibody) which is held by Abbott. Blood tests are expensive. Especially in the developing world. The Affimer assay would need less sample preparation than a total vitamin B12 test and cost far less.

Which will detect ‘active’ B12 and enable #AVCT to work around the existing IP (antibody) which is held by Abbott. Blood tests are expensive. Especially in the developing world. The Affimer assay would need less sample preparation than a total vitamin B12 test and cost far less.It is, in my opinion, this type of IP evasion by #AVCT which will get them noticed. This is why they are working on B12 assays quietly. Not because it is a huge money spinner (though 200m at 7.2% CAGR is not to sniffed at for a £300m m cap) but because they know as soon as youStart to evade Abbott’s IP, you’re noticed by their research and sales teams and the Affimer (and it’s wider application) begins to gain traction as they ask what other areas will this small company be seeking to disrupt? Another area they will seek to play in, imo, is Sepsis.1.1Bn USD by 2027, expanding at 9.4% CAGR. Sepsis caused 270k deaths in the US w/2m people contracting. If you can market an Affimer based assay which enables clinicians to differentiate between bacterial and viral infections you enable better antibiotic prescription.Start to evade Abbott’s IP, you’re noticed by their research and sales teams and the Affimer (and it’s wider application) begins to gain traction as they ask what other areas will this small company be seeking to disrupt? Another area they will seek to play in, imo, is Sepsis.

the tread
LFT demand (without covid) was another reason for my 117p purchase of #AVCT yesterday. Most investors are focussed on either AffiDx or AVA6000. However, if one looks beyond these short term drivers to the post-covid LFT potential, I think they will be pleasantly surprised.The size and the scope of the non-Covid LFT market is expansive. All driven by Affimers. Some assays in this area are under licence (such as B12 w/the licence held by Abbott) but others are not. This presents huge opportunity.A B12 efficiency can cause anaemia. The current blood test only measures the amount of B12 is the blood and not whether it is ‘active’ or not. This market is worth around 200m USD and growing at a CAGR of 7.2%. I understand #AVCT to be working on an affimer assay

beinthelead; don't providers have the responsibility of gathering proof and submitting to DHSC. It is a strong border protection with the £1k/£2k fines for non compliance, other countries are employing/contemplating a broad sweep approach to UK ie noone from there allowed into their country. https://www.express.co.uk/travel/articles/1510067/UK-travel-ban-countries-ban-UK-flights-Morocco-half-term-evg but I prefer ours-opening up is a must.
I am glad about this https://www.politico.eu/article/uk-boris-johnson-break-science-funding-pledge-budget-coronavirus/ as big pharma has profited from covid I imagine and can fund themselves however he must break the link of regulators being influenced by big pharma and national spies/lobbies on the panels. The members should also be protected from any bad decisions by insurance and procedures speeded up in times of quick AI and willing human research material (in a tube or other means), I think animals used in research is wrong.
The application of no blame insurance cover is also a priority for surgeons in order to reduce the legal payouts and time wasting and bad blood! blame culture in the NHS as the Swedes do their insurance for surgeons. It just seems like another institutional gravy train for lawyers.

Thats great Vascular, we can be 'unknown' on the EU Ehrlich list; you have to laugh at procedures. Just hope 'is it us'

Maybe BIRD is not 'on the market' yet. McDonough hasn't started the auction yet. Strategy is to build brand then sell but SS will have to be part of the package. Difficult space to build market share even if BIRD deserves it.

This is a real catch, he is a great addition
Commenting on his appointment Bhav Singh added:

"I am delighted to be joining the GBG Board at such an exciting time for the Company as it continues its journey and growth trajectory. I look forward to serving on the Board in this time of growth and with such huge opportunities ahead."

It will probably reverse but to hedge the overnight UT I used the extra funds to open a bigger gold spread bet just in case that would offset an almost inevitable lower open. It has worked well this time atm.

unvaccinated should be regarded as the prized control group for putting themselves in more danger of serious illness. Everyone should be safeguarded with AffiDX where outbreaks occur. Come on Javid and Johnson never mind "Johnson & Johnson is collaborating with governments, regulators, healthcare organisations, institutions and communities worldwide to help ensure our research platforms, existing science and outbreak expertise can be maximised to help stem this pandemic." https://jnj.co.uk/coronavirus